Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M. Kileel, Heather J Ribaudo, Markella V. Zanni et al.|The Lancet HIV|2026Cited by 2